Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

OBJECTIVE: To evaluate individual and group long-term efficacy and safety of erenumab in individuals with episodic migraine (EM) for whom 2–4 prior preventatives had failed. METHODS: Participants completing the 12-week double-blind treatment phase (DBTP) of the LIBERTY study could continue into an o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Michel Dominique, Reuter, Uwe, Goadsby, Peter J, Paiva da Silva Lima, Gabriel, Mondal, Subhayan, Wen, Shihua, Tenenbaum, Nadia, Pandhi, Shaloo, Lanteri-Minet, Michel, Stites, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Migraine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862066/
https://www.ncbi.nlm.nih.gov/pubmed/34845002
http://dx.doi.org/10.1136/jnnp-2021-327480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862066/
https://www.ncbi.nlm.nih.gov/pubmed/34845002
http://dx.doi.org/10.1136/jnnp-2021-327480

Ejemplares similares